# OnCo record nct04153734 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct04153734/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct04153734", "NCT04153734" ;
  schema:name "Pembrolizumab + Platinum Doublets Without Radiation for Programmed Death-ligand 1 (PD-L1) ≥50% Locally Advanced NSCLC"@en ;
  schema:alternateName "Evolution"@en ;
  schema:description "A phase 2 trial of pembrolizumab, carboplatin, pemetrexed and nab-paclitaxel in lung cancer, run by Kobe Minimally Invasive Cancer Center, not yet recruiting."@en ;
  schema:url <https://onco.cc/trials/nct04153734/> ;
  schema:dateModified "2026-09-25"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT04153734> ;
  onco:status "planned" ;
  onco:tag "ctgov-ingest", "lung-deep-dive" ;
  onco:phase "2" ;
  onco:cancers <https://onco.cc/cancers/stage-iii-unresectable-nsclc/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/platinum/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/pemetrexed/>, <https://onco.cc/drugs/nab-paclitaxel/> .